Clinical Trials

Phase 2a study (Part 1) A phase 2a study to evaluate the safety, pharmacokinetics and clinical activity of the PI3K/mTOR inhibitor GDC-0084 administered to patients with glioblastoma multiforme characterized by unmethylated O6-methylguaninemethyltransferase promoter status Phase 2b study (Part 2) A randomized, open-label, multicenter, phase 2b study to assess the efficacy and safety of the PI3K/mTOR inhibitor GDC-0084 compared to temozolomide as adjuvant therapy for the treatment of newly diagnosed glioblastoma multiforme with unmethylated O6-methylguanine-methyltransferase promoter status following surgical resection and standard concomitant chemoradiation therapy with temozolomide


Study ID
Kazia Novogen NVGN-0084-201

NCT Number
NCT03522298 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0152

Principle Investigator
Dr. Samuel Goldlust

Phase
II

Sponsor
Novogen


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now